Anbio Biotechnology Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Non-COVID IVD Revenue Share Annually80.4%Target: Continued diversification and expansion of non-COVID diagnostic portfolio
Annual Revenue Annually8.7MTarget: Long-term growth driven by global IVD market expansion
Gross Profit Margin Annually87.2%Target: Maintain high margins through outsourcing-led model and high-margin product mix
Watch Items
- Regulatory Approvals for IVD ProductsTrigger: Obtaining IVDR compliance in the EU and FDA clearances in the USAction: Monitor regulatory filings, clinical validation progress, and compliance updates
- Customer Concentration RiskTrigger: High concentration of sales in the European Union and with key distributorsAction: Track geographic revenue breakdown and expansion of sales networks in APAC and the Americas
- Dual-Class Share Structure and Voting ControlTrigger: Class B shares carry 500 votes per share, concentrating voting power with founding shareholdersAction: Evaluate corporate governance developments and potential impacts on minority shareholders
Research as of 19 Jun 2026